In a Phase I trial, single-agent CD19 CAR-NK natural killer cell therapy has achieved complete responses in two patients with third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkins lymphoma (NHL). 

QUILT-106 is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone and in combination with rituximab in patients with relapsed or refractory (R/R) CD19⁺CD20⁺ B-cell NHL.  

The disease remains challenging to treat, and WM is considered incurable with existing treatment options. 

In the first two evaluable patients with WM who were heavily pretreated, the regimen was tolerated with no significant toxicities. Notably, all infusions (including CAR-NK cells and cytokines) were administered in an outpatient setting.  

One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date. 

The open-label study, sponsored by ImmunityBio, is enrolling 12 patients with NHL at three sites in South Africa. Eligible study participants express CD19 and CD20, with active disease after ≥2 chemotherapy-based lines of treatment.  

All patients receive a lead-in cycle of CD19 CAR-NK cell monotherapy, followed by a one-week observation pause, then a second cycle combining CD19 CAR-NK with rituximab. 

“The preliminary findings we have submitted for presentation at the American Society of Haematology annual meeting provides the first evidence that novel immunotherapy combinations without chemotherapy lymphodepletion can provide deep and durable remissions in WM even after multiple prior treatments,” said Dr Jackie Thomson, Wits University Donald Gordan Medical Center, Johannesburg, South Africa and the lead author of the paper. “Recruitment in this rare subset of lymphoma is ongoing to confirm these findings and to establish this chemo-free strategy as a viable treatment option for relapsed WM.”

Diana Turner, Senior Digital Content Editor, DDW